甘精胰岛素联合格列吡嗪控释片治疗2型糖尿病

Study on the efficacy and safety of Insulin Glargine combined with Glipizide GITS in the treatment of type 2 diabetes mellitus

目的探讨超长效重组甘精胰岛素与中效胰岛素联合口服格列吡嗪控释片治疗2型糖尿病的疗效比较。方法60例口服降糖药血糖控制不理想的2型糖尿病患者按1∶1随机分为甘精胰岛素治疗组和诺和灵N组。观察血糖控制和低血糖事件发生频率,以及空腹血糖(FBG)达标时所用甘精胰岛素和诺和灵N的剂量。结果治疗后两组FBG及全天血糖谱均较基线水平明显下降,两组下降幅度比较差异无显著性,甘精胰岛素组HbA1c达标率(29·63%)明显高于诺和灵N组(5·28%)。甘精胰岛素组夜间低血糖发生率明显低于诺和灵N组。结论清晨口服长效降糖药联合睡前注射1次超长效甘精胰岛素可使更多控制不佳的2型糖尿病患者血糖达标,并能减少夜间低血糖发生。

Objective To compare the blood glucose level and associated hypoglycemia risks between using insulin Glargine or human NPH both combined with Glipizide GITS in the Treatment of Type 2 diabetic patients. Methods Sixty cases with inadequate glycemia control induced by sulfonylurea and/or other oral agents were randomized into two groups （ 1 ： 1 ）. The blood glucose level and incidence of hypoglycemia were observed. The daily dosages of Glargine and NPH were recorded. Results Mean of FBG and daily glucose profile were similar to that in the 2 groups, but the incidence of hypoglycemia at night in the Glargine group was significantly lower than that in the NPH group（P 〈 0. 05 ）. Conclusion Bedtime injection of Glargine combined with Glipizide Girl＇S can achieve blood glucose control target and be safer than using NPH.